Evidence map›Paper›PMID 39423292›Full record

ArticleBrain : a journal of neurology2025

Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults.

Kirsty Lu, John Baker, Jennifer M Nicholas, Rebecca E Street, Sarah E Keuss, William Coath, Sarah-Naomi James, Ashvini Keshavan, Philip S J Weston, Heidi Murray-Smith and 7 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Progress on prognostic assessment methods for mild cognitive impairment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kirsty LuDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.ORCID 0000-0002-8416-2183
John BakerDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Jennifer M NicholasDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Rebecca E StreetDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Sarah E KeussDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
William CoathDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.ORCID 0000-0002-3976-9461
Sarah-Naomi JamesMRC Unit for Lifelong Health and Ageing at UCL, University College London, London, WC1B 5JU, UK.ORCID 0000-0002-3800-4416
Ashvini KeshavanDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Philip S J WestonDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Heidi Murray-SmithDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
David M CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.ORCID 0000-0001-7833-616X
Ian B MaloneDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.ORCID 0000-0001-7512-7856
Andrew WongMRC Unit for Lifelong Health and Ageing at UCL, University College London, London, WC1B 5JU, UK.
Nick C FoxDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Marcus RichardsMRC Unit for Lifelong Health and Ageing at UCL, University College London, London, WC1B 5JU, UK.ORCID 0000-0001-9191-2192
Sebastian J CrutchDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.
Jonathan M SchottDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3AR, UK.ORCID 0000-0003-2059-024X

Funding

Alzheimer's Association SG-666374-UK BIRTH COHORTAlzheimer's Research UK ARUK-PG2014-1946Alzheimer's SocietyAlzheimer's Society and Alzheimer's Research UKAVID RadiopharmaceuticalsBrain Research Trust UCC14191British Heart Foundation PG/17/90/33415Care Research University College London Hospitals Biomedical Research CentreDRI LtdEli LillyEngineering and Physical Sciences Research Council EP/J020990/1EU's Horizon 2020 research and innovation programme 666992Medical Research Council MC_UU_10019/1Medical Research Council Dementias Platform UK CSUB19166National Institute for HealthNational Institute for Health ResearchRosetrees TrustSelfridges Foundation UB170045UK Dementia Research InstituteUK Medical Research CouncilUKRI Innovation Scholars: Data Science Training in Health and Bioscience MR/V03863X/1University College London UKDRI-1003University College London Hospitals Biomedical Research CentreWeston Brain InstituteWolfson Clinical Research FellowshipWolfson Foundation PR/ylr/18575
6 · The paper itself

Abstract

Accelerated long-term forgetting (ALF) is the phenomenon whereby material is retained normally over short intervals (e.g. minutes) but forgotten abnormally rapidly over longer periods (days or weeks). ALF might be an early marker of cognitive decline, but little is known about its relationships with preclinical Alzheimer's disease pathology and how memory selectivity might influence which material is forgotten. We assessed ALF in 'Insight 46', a sub-study of the MRC National Survey of Health and Development (a population-based cohort born during the same week in 1946) (n = 429; 47% female; assessed at age ∼73 years). ALF assessment comprised visual and verbal memory tests: complex figure drawing and the face-name associative memory exam (FNAME). ALF scores were calculated as the percentage of material retained after 7 days, relative to 30 min. In 306 cognitively normal participants, we investigated effects on ALF of β-amyloid pathology (quantified using 18F-Florbetapir-PET, classified as positive/negative) and whole-brain and hippocampal atrophy rate (quantified from serial T1-MRI over ∼2.4 years preceding the ALF assessment), in addition to interactions between these pathologies. We categorized complex figure drawing items as 'outline' or 'detail', to test our hypothesis that forgetting the outline of the structure would be more sensitive to the effect of brain pathologies. We also investigated associations between ALF and subjective cognitive decline, measured with the MyCog questionnaire. Complex figure 'outline' items were better retained than 'detail' items (mean retention over 7 days = 94% versus 72%). Amyloid-positive participants showed greater forgetting of the complex figure outline compared with amyloid-negative participants (90% versus 95%; P < 0.01). There were interactions between amyloid pathology and cerebral atrophy, such that whole-brain and hippocampal atrophy predicted greater ALF on complex figure drawing among amyloid-positive participants only [e.g. 1.9 percentage-points lower retention per ml/year of whole-brain atrophy (95% confidence intervals 0.5, 3.7); P < 0.05]. Greater ALF on FNAME was associated with increased rate of hippocampal atrophy. ALF on complex figure drawing was also correlated with subjective cognitive decline [-0.45 percentage-points per MyCog point (-0.85, -0.05); P < 0.05]. These results provide evidence of associations between some measures of ALF and biomarkers of brain pathologies and subjective cognitive decline in cognitively normal older adults. On complex figure drawing, 'outline' items were better remembered than 'detail' items, illustrating the strategic role of memory selectivity, but 'outline' items were also relatively more vulnerable to ALF in individuals with amyloid pathology. Overall, our findings suggest that ALF might be a sensitive marker of cognitive changes in preclinical Alzheimer's disease.

Indexed as

Amyloid beta-PeptidesBrainMemory DisordersAgedAged, 80 and overAlzheimer DiseaseAtrophyCognitive DysfunctionCohort StudiesFemaleHippocampusHumansMagnetic Resonance ImagingMaleNeuropsychological TestsPositron-Emission TomographyAmyloid beta-PeptidesageingAlzheimer's diseaseamyloidatrophyneuropsychologysubjective cognitive decline

Identifiers

PMID39423292
PMCPMC11969454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.